SCHEMBL5483443

SCHEMBL5483443

CC(=O)Oc1ccc(C2(c3ccc(OC(C)=O)cc3)C(=S)Nc3sc(Cl)cc32)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.43
LMNA P02545 3/20 0.36
KDM4E B2RXH2 3/20 0.33
POLB P06746 1/20 0.33
PKM P14618 1/20 0.33
MEN1 O00255 1/20 0.33
TTR P02766 1/20 0.33
TP53 P04637 1/20 0.33
CYP3A4 P08684 1/20 0.33
KMT2A Q03164 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
ELANE P08246 1/20 0.33
KIF11 P52732 1/20 0.32
HSD17B10 Q99714 1/20 0.32
GAA P10253 3/20 0.31
ALDH1A1 P00352 1/20 0.31
HSP90AA1 P07900 1/20 0.31
CA2 P00918 2/20 0.31
CA5A P35218 1/20 0.31
ACHE P22303 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5482736 0.86 MAPT (0.56) MAPTLMNAKDM4EPOLBPKM
SCHEMBL5488975 0.76 MAPT (0.43) MAPTLMNAKDM4EPOLBPKM
SCHEMBL5480076 0.73 MAPT (0.43) MAPTLMNAKDM4EPOLBPKM
Lithium SCHEMBL30522746 0.64 LMNA (0.76) MAPTLMNAKDM4EPOLBPKM
SCHEMBL5483571 0.64 MAPT (0.56) MAPTLMNAKDM4EPOLBPKM
SCHEMBL5485414 0.64 MAPT (0.60) MAPTLMNAKDM4EPOLBPKM
SCHEMBL11940933 0.63 MAPT (0.62) MAPTLMNAKDM4EPOLBPKM
SCHEMBL269329 0.62 LMNA (0.80) MAPTLMNAKDM4EPOLBPKM
SCHEMBL5482053 0.62 MAPT (0.56) MAPTLMNAKDM4EPOLBPKM
SCHEMBL13578396 0.62 MAPT (0.47) MAPTLMNAKDM4EPOLBPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US claimed
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US disclosed
EP-1734951-A2 DIPHENYL-INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER TopoTarget A/S (DK) 2006-12-27 EP disclosed
WO-2005097107-A2 DIPHENYL - INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER TOPOTARGET A/S (DK) 2005-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer MTOR, RICTOR, CDK4 MAPT 1785/4885LMNA 3104/4885KDM4E 420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.